Gary Lyman, MD, MPH, an oncologist and hematologist, compares the uptake of filgrastim biosimlars with pegfilgrastim biosimilars. Gary Lyman, MD, MPH, is an oncologist, hematologist, and public health ...

The "Filgrastim Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com’s offering. Major players in the filgrastim biosimilars market are ...

Previous studies have found modest uptake of biosimilars in both commercial and Medicare populations. This study finds that the uptake varies between the rural and urban provider settings. Biosimilars ...

Releuko ® (filgrastim-ayow), a biosimilar to Neupogen ® (filgrastim), is now available in the US for the treatment of neutropenia. Releuko, a leukocyte growth factor, is indicated to: Decrease the ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of RELEUKO® (filgrastim-ayow), a biosimilar referencing ...

Association of Community-Level Social Vulnerability With Clinical Trial Discussion and Participation Among Cancer Survivors This was an observational, noninferiority, cohort study of patients from ...

PISCATAWAY, N.J.--(BUSINESS WIRE)--U.S.-based Adello Biologics today announced that U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) ...

The approval of biosimilars in the U.S. is lagging behind that of European countries, a pharmacist said during the American Society of Health-System Pharmacists (ASHP) Midyear virtual meeting. While ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. On July 28th, the Food and Drug Administration (FDA) approved the ...